Parkinson’s drugs may lead to compulsive behaviours such as gambling

Special reports

Author: Simge Eva DoganPublished: 9 July 2018

Prep: Cook: Serves:

Common Parkinson’s drugs may cause patients to develop disorders including compulsive gambling, shopping, eating and sexual behaviours, a new study suggests

Researchers at the Sorbonne University, Paris, France have conducted a study that has found a link between common Parkinson’s drugs and compulsive behaviours – including gambling and shopping.

The study examined 411 people with Parkinson’s for an average duration of three years, during which they were interviewed about impulse control disorders.

In the group who had taken the dopamine agonist drugs, 52% went on to develop impulse control disorders. In comparison, 12% in the group who had not taken the drugs struggled with the disorders.

In addition, the study suggested those taking a higher dose of dopamine agonists are at a greater risk of impulse control disorders.

Dr Jean-Christophe Corvol, assistant professor in neuro-pharmacology at the Pitié-Salpêtrière Hospital in Paris, France and author of the study published in medical journal ‘Neurology’, said: “Our study suggests that impulse control disorders are even more common than we thought in people who take dopamine agonists.

“These disorders can lead to serious financial, legal and social and psychological problems.”

Impulse control disorders had been identified as common in people with Parkinson’s disease prior to the study. However, these findings have established a clear relationship between dopamine replacement therapy and the disorders.

Commenting on the study, Dr Laura S Boylan, neurologist at New York University US, said: “These disorders can be challenging for neurologists to discover.

“People might be ashamed to tell their doctor about their problems – they may think these issues are not related to their Parkinson’s disease, or they may not even consider the disorders a problem.”

For more information on compulsive and impulsive behaviour visit the EPDA website.

App improves adherence to Parkinson’s meds

Last Month

Next Month

Go Back

Share this story

Comments

AnneHaan

My husband has Parkinson’s dissease. His neurologist prescribed him Sifrol (pramipexol). As a result of that drug he developed a gamb;ling addiction which finally led us into severe debt. We went into debt restructuring and lived on the absolute minimum for 3 years. Now we are cleared and can live normally again. My husband will never take a dopamine agonist again!

PD in Practice

Over 1/3 of patients don’t receive enough info about Parkinson’s at diagnosis

Parkinson’s UK outlines key areas for improvement in care in audit

Olie Westheimer: the visionary behind Dance for PD

Award-winner speaks about her work in the Parkinson’s community

Scientists ‘revive’ foetal implant treatment for Parkinson’s

Foetal cells are injected into a man's brain to 'cure' his Parkinson's

IBM unveils AI-powered fingernail sensor that can monitor Parkinson’s progression

US information technology giant IBM has unveiled a prototype of the first artificial intelligence (AI) powered fingernail sensor designed to track disease progression. The AI system – a wireless device that attaches to the fingernail – monitors the movement of the patient’s nail and calculates their grip strength. Data gathered is then used to determine how the wearer’s grip has changed over time, and also tracks symptoms such as bradykinesia, tremor and dyskinesia. Katsuyuki Sakuma, a researcher at IBM’s Thomas J. Watson Research Centre, New York US, said: “Our fingernails deform — bend and move — in stereotypic ways when we use them for gripping, grasping, and even flexing and extending our fingers. This deformation is usually on the order of single digit microns and not visible to the naked eye. “By pushing computation to the end of our fingers, we’ve found a new use for our nails by detecting and characterising their subtle movements.”

Inhalable drug given green light

The US Food and Drug Administration (FDA) has approved INBRIJA – an inhalable drug created by US biotech company Acorda Therapeutics – for intermittent treatment. INBRIJA is designed to treat Parkinson’s symptoms that occur between oral doses of medication, which are known as ‘off’ episodes. The drug has been approved by the FDA and – after a clinical study involving 900 people with Parkinson’s – is expected to be available in 2019. Todd Sherer, CEO of The Michael J Fox Foundation, who funded early trials of the powder, said: “Despite being on treatment, patients may experience OFF periods as Parkinson’s progresses, which can be disruptive. “We knew we had to help address this unmet need, and this approval is a significant step forward for the community as it provides a new option to manage these gaps in symptom control.”

Researchers create Parkinson’s-resistant stem cells

Scientists at the University of Edinburgh, UK, have created stem cells that they say are resistant to developing Parkinson’s. The study – published in science journal ‘European Journal of Neuroscience’ – used gene editing techniques to remove the alpha-synuclein protein from the stem cells. To test the resistance of the new stem cells, researchers treated both edited and unedited stem cells with a chemical agent that induced Lewy bodies – abnormal proteins that lead to neurodegeneration. The results showed that the gene-edited cells did not develop signs of Parkinson’s, whereas the unedited cells did. Dr Tilo Kunath – who led the study – said: “We know that Parkinson’s disease spreads from neuron-neuron, invading healthy cells. This could essentially put a shelf life on the potential of cell replacement therapy. Our exciting discovery has the potential to considerably improve these emerging treatments.”

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
*
- By proceeding you agree to our
Comments
This field is for validation purposes and should be left unchanged.

Parkinson’s drugs may lead to compulsive behaviours such as gambling

Special reports

Author: Simge Eva DoganPublished: 9 July 2018

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

PD in Practice

Over 1/3 of patients don’t receive enough info about Parkinson’s at diagnosis

Interviews

Olie Westheimer: the visionary behind Dance for PD

Advances

Scientists ‘revive’ foetal implant treatment for Parkinson’s

IBM unveils AI-powered fingernail sensor that can monitor Parkinson’s progression

Inhalable drug given green light

Researchers create Parkinson’s-resistant stem cells

{title}

Subscribe

Parkinson’s drugs may lead to compulsive behaviours such as gambling

Special reports

Author: Simge Eva DoganPublished: 9 July 2018

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Related articles

PD in Practice

Over 1/3 of patients don’t receive enough info about Parkinson’s at diagnosis

Interviews

Olie Westheimer: the visionary behind Dance for PD

Advances

Scientists ‘revive’ foetal implant treatment for Parkinson’s

IBM unveils AI-powered fingernail sensor that can monitor Parkinson’s progression

Inhalable drug given green light

Researchers create Parkinson’s-resistant stem cells

{title}

Subscribe

Sign in